Metabolic Factors Affecting Residual Beta Cell Function Assessed by C-Peptide Secretion in Patients with Newly Diagnosed Type 1 Diabetes

Abstract

Background: In recent onset of type 1 diabetes, the residual beta cell function, assessed by baseline and/or stimulated C-peptide secretion, can be a useful parameter to establish the extension of beta cell destruction. How metabolic parameters at diagnosis influence residual C-peptide secretion is not well established. Patients and Methods: We analyzed 553 consecutive patients with recent onset (<4 weeks) of type 1 diabetes (250 females and 303 males, mean age 15±8 years). Baseline and stimulated C-peptide by i.v. glucagon were evaluated using a highly sensitive radio-immunoassay. Metabolic parameters including blood glucose, HbA1c, insulin dose, and BMI were also evaluated. Results: Baseline and stimulated C-peptide were 0.26±0.22 and 0.47±0.38 nmol/l and correlated positively with age (p<0.001). There was no significant correlation between C-peptide and blood glucose at diagnosis. BMI was positively correlated with both baseline and stimulated C-peptide secretion (p<0.001). By contrast, HbA1c levels inversely correlated with both baseline and stimulated C-peptide secretion (p<0.001). Conclusion: In type 1 diabetes at diagnosis, baseline and stimulated C-peptide are higher in pubertal and young adult patients compared with pre-pubertal patients suggesting that such parameter can be used as an end point marker for studies aimed at protecting and/or restoring beta cells in patients with substantial beta cell function. High levels of HbA1c and lower BMI are dependent variables of C-peptide values.

Key words

Baseline and stimulated C-peptide - type 1 diabetes - HbA1c - insulin dose

References

• 1 Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.  Diabetes. 2004;  53 250-264
• 2 Petrone A, Galgani A, Spoletini M, Alemanno I, Di Cola S, Bassotti G, Picardi A, Manfrini S, Osborn J, Pozzilli P, Buzzetti R. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both age of onset and HLA genotype.  Diabetes Metab Res Rev. 2005;  21 271-275
• 3 Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes.  Diabetes. 2004;  53 426-433
• 4 Wilson DM, Buckingham B. Prevention of type 1 diabetes mellitus.  Pediatr Diabetes. 2001;  2 17-24
• 5 Crino A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P. IMDIAB Group . A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).  Eur J Endocrinol. 2004;  150 719-724
• 6 Winter WE, Schatz D. Prevention strategies for type 1 diabetes mellitus: current status and future directions.  Bio-Drugs. 2003;  17 39-64
• 7 Atkinson MA. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?.  Diabetes. 2005;  54 1253-1263
• 8 Herold KC. Treatment of type 1 diabetes mellitus to preserve insulin secretion.  Endocrinol Metab Clin North Am. 2004;  33 93-111
• 9 Greenbaum CJ. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials.  Clin Immunol. 2002;  104 97-104
• 10 Lombardo F, Valenzise M, Wasniewska M, Messina MF, Ruggieri C, Arrigo T, De Luca F. Two year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis.  Diabetes Nutr Metab. 2002;  15 246-251
• 11 Pozzilli P, Visalli N, Buzzetti R, Cavallo MG, Marietti G, Hawa M, Leslie RD. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes. A population-based Study. IMDIAB Study Group.  Metabolism. 1998;  47 1205-1210
• 12 Salardi S, Zucchini S, Cicognani A, Corbelli E, Santoni R, Ragni L, Elleri D, Cacciari E. The severity of clinical presentation of type 1 diabetes in children does not significantly influence the pattern of residual beta-cell function and long-term metabolic control.  Pediatr Diabetes. 2003;  4 4-9
• 13 Sugihara S, Sakamaki T, Konda S, Murata A, Wataki K, Kobayashi Y, Minamitani K, Miyamoto S, Sasaki N, Niimi H. Association of HLA-DR, DQ genotype with different beta-cell functions at IDDM diagnosis in Japanese children.  Diabet Med. 1999;  16 201-206
• 14 Zevaco-Mattei C, Reviron D, Atlan-Gepner C, Botti G, Simonin G, Lassmann-Vague V, Vague P, Mercier P, Vialettes B. Relationship between HLA-DQ and -DR genotypes and clinical characteristics in a French population of Type 1 diabetic patients.  Diabetes. 1997;  46 1893-1897
• 15 Vanelli M, Chiari G, Ghizzoni L, Costi G, Giacalone T, Chiarelli F. Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices.  Diabetes Care. 1999;  22 7-9
• 16 Pozzilli P, Visalli N, Buzzetti R, Cavallo MG, Marietti G, Hawa M, Leslie RD. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIAB Study Group. Immunotherapy Diabetes.  Metabolism. 1998;  47 1205-1210
• 17 Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus.  Diabet Med. 1998;  15 844-850
• 18 Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes.  Diabetes Care. 2000;  23 1326-1332
• 19 Olsen BS, Sjolie A, Hougaard P, Johannesen J, Borch-Johnsen K, Marinelli K, Thorsteinsson B, Pramming S, Mortensen HB. A 6-year nationwide cohort study of glycaemic control in young people with type1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood.  J Diabetes Complications. 2000;  14 295-300
• 20 Olsen BS, Sjolie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, Mortensen HB. Danish Study Group of Diabetes in Childhood . The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes.  J Diabetes Complications. 2004;  18 160-164
• 21 Greenbaum CJ, Harrison LC. On behalf of the Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.  Diabetes. 2003;  52 1059-1065
• 22 Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.  Diabetes Care. 2003;  26 832-836

Correspondence